Impax Laboratories Inc  

(Public, NASDAQ:IPXL)   Watch this stock  
Find more results for Jeffrey Wilkinson´┐Ż
+0.70 (1.59%)
After Hours: 44.75 -0.01 (-0.02%)
Dec 1, 4:52PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 43.56 - 45.00
52 week 28.31 - 52.10
Open 44.25
Vol / Avg. 868,763.00/918,251.00
Mkt cap 3.14B
P/E 119.54
Div/yield     -
EPS 0.37
Shares 70.51M
Beta 1.23
Inst. own 99%
Feb 22, 2016
Q4 2015 Impax Laboratories Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 8, 2015
Impax Laboratories Inc Extraordinary Shareholders Meeting - 7:00PM EST - Add to calendar
Nov 11, 2015
Impax Laboratories Inc at Credit Suisse Healthcare Conference
Nov 9, 2015
Q3 2015 Impax Laboratories Inc Earnings Release
Nov 9, 2015
Q3 2015 Impax Laboratories Inc Earnings Call
Sep 18, 2015
Impax Laboratories Inc at Morgan Stanley Healthcare Conference
Sep 8, 2015
Impax Laboratories Inc Announces Resolution of FDA Warning Letter Related to its Hayward Manufacturing Facility Conference Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 16.17% 9.62%
Operating margin 12.46% 14.90%
EBITD margin - 21.99%
Return on average assets 7.12% 5.53%
Return on average equity 14.22% 6.76%
Employees 1,061 -
CDP Score - -


30831 Huntwood Ave
HAYWARD, CA 94544-7003
United States - Map
+1-510-2406000 (Phone)
+1-510-4713200 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. The Company operates in two segments: Impax Generics and Impax Specialty Pharma. The Impax Generics is focused on the development, manufacture, sale and distribution of the Company's generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma is engaged in the development of brand pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Impax Specialty Pharma is also engaged in the sale and distribution of Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Officers and directors

Robert L. Burr Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
G. Frederick Wilkinson President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Bryan M. Reasons Chief Financial Officer, Senior Vice President - Finance
Age: 47
Bio & Compensation  - Reuters
Michael J. Nestor President - Impax Pharmaceutical Division
Age: 62
Bio & Compensation  - Reuters
Deborah Penza Senior Vice President, Chief Compliance Officer
Bio & Compensation  - Reuters
Mark A. Schlossberg Esq. Senior Vice President, General Counsel, Corporate Secretary
Age: 54
Bio & Compensation  - Reuters
Donna Marie Hughes Senior Vice President of Human Resources
Bio & Compensation  - Reuters
Jeffrey D Nornhold Senior Vice President - Technical Operations
Age: 49
Bio & Compensation  - Reuters
Janet S. Vergis Director
Age: 51
Bio & Compensation  - Reuters
Leslie Z. Benet Ph.D. Independent Director
Age: 77
Bio & Compensation  - Reuters